Topic: Cell Therapy

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.

Gene and cell therapies will make strides in 2020, but their developers will have to address challenges in manufacturing, reimbursement and more.

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.

With drugmakers focused on gene therapies, recombinant proteins supplier Bio-Techne says it will build a new plant to boost capacity.

Cigna's new program that will cover Novartis' Zolgensma and Spark's Luxturna, both pricey gene therapies, at no cost to patients.

Lonza is continuing an expansion binge for its pharma manufacturing as it leans more heavily on it to drive its growth. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.